



US008796331B2

(12) **United States Patent**
Ksander et al.

(10) **Patent No.:** US 8,796,331 B2
(45) **Date of Patent:** Aug. 5, 2014

- (54) **METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION**
- (71) Applicant: **Novartis AG**, Basel (CH)
- (72) Inventors: **Gary Michael Ksander**, Milford, NJ (US); **Randy Lee Webb**, Flemington, NJ (US)
- (73) Assignee: **Novartis AG**, Basel (CH)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/687,659**(22) Filed: **Nov. 28, 2012**(65) **Prior Publication Data**

US 2013/0158086 A1 Jun. 20, 2013

Related U.S. Application Data

- (62) Division of application No. 13/328,769, filed on Dec. 16, 2011, now Pat. No. 8,404,744, which is a division of application No. 12/147,570, filed on Jun. 27, 2008, now Pat. No. 8,101,659, which is a division of application No. 10/341,868, filed on Jan. 14, 2003, now Pat. No. 7,468,390.
- (60) Provisional application No. 60/386,792, filed on Jun. 7, 2002, provisional application No. 60/349,660, filed on Jan. 17, 2002.

(51) **Int. Cl.**

A61K 31/235 (2006.01)
A61K 31/41 (2006.01)
A61K 31/195 (2006.01)

(52) **U.S. Cl.**USPC **514/533; 514/381; 514/561; 514/563**(58) **Field of Classification Search**USPC 514/533, 381, 561, 563
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

4,610,816 A	9/1986	Berger	549/452
4,722,810 A	2/1988	Delaney et al.	260/402.5
4,740,499 A	4/1988	Olins	514/13
4,749,688 A	6/1988	Haslanger et al.	514/19
4,929,641 A	5/1990	Haslanger et al.	514/506
5,217,996 A	6/1993	Ksander	514/533
5,223,516 A	6/1993	Delaney et al.	514/339
5,273,990 A	12/1993	De Lombaert	514/381
5,294,632 A	3/1994	Erion et al.	514/381
5,399,578 A	3/1995	Bühlmayer et al.	514/381
5,520,522 A	5/1996	Rathore et al.	417/322
7,423,032 B2 *	9/2008	Ozaki et al.	514/213.01

FOREIGN PATENT DOCUMENTS

EP	0 342 850	11/1989
EP	0 343 911	11/1989
EP	0 361 365	4/1990
EP	0 443 983	8/1991

EP	0 498 361	8/1992
EP	555175	1/1993
EP	0 636 621	2/1995
EP	0726072	2/1996
EP	0 726 072	8/1996
EP	0636621 B1	3/1997
GB	2 218 983	11/1989
WO	90/09374	8/1990
WO	92/14706	9/1992
WO	93/09101	5/1993
WO	93/10773	6/1993
WO	94/15908	7/1994
WO	01/74348	10/2001
WO	01/97805 A2	12/2001
WO	02/06253	1/2002
WO	02/092622	11/2002
WO	03/066606	8/2003

OTHER PUBLICATIONS

Lajemi et al., "Genetics of the renin-angiotensin aldosterone system and risk of arterial disease", ACE Inhibitors, Milestones in Drug Therapy, pp. 11-27; P. D'Orleans Juste, G.E. Plante (2001).
Matsumoto et al., "Blockade of renin-angiotensin system and enhancement of atrial natriuretic peptide with neutral endopeptidase inhibition cause natriuresis in congestive heart failure and renal dysfunction in conscious dogs", ASN Program and Abstracts, vol. 4, No. 3, p. 517 (Sep. 1993).
Robi et al., "Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin converting enzyme", Antihypertensive Drugs, pp. 113-212, (1997).

(Continued)

Primary Examiner — Jennifer M Kim(74) *Attorney, Agent, or Firm* — Matthew Mulkeen(57) **ABSTRACT**

The invention relates a pharmaceutical composition comprising a combination of:

- (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and
- (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, diabetic retinopathy, the management of other vascular disorders, cognitive dysfunction, comprising administering a therapeutically effective amount of the pharmaceutical composition to mammal in need thereof.

10 Claims, No Drawings